The global ESR1 mutated metastatic breast cancer diagnostics industry is poised for significant expansion, with an anticipated year-over-year (y-o-y) growth rate of 4.0%. The market size is projected to grow from USD 63.4 million in 2024 to USD 89.6 million by 2034, reflecting a compound annual growth rate (CAGR) of 3.7% during the forecast period. …